MALVERN, Pa., May 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA –IIA Cutaneous T Cell Lymphoma will be presented at the annual Society of Investigative Dermatology Meeting to be held in Albuquerque, New Mexico from May 7– May 10, 2014.
The date and time of the poster presentation are as follows:
- Date & Time: Thursday, May 8, 2014 at 12.15pm to 12.25pm
Session: Cutaneous T Cell Lymphoma Symposium
International Society for Cutaneous Lymphoma (ISCL) Scientific and Annual General Meeting
Presentation Title: Tolerability and Encouraging Clinical Activity of SHP-141, a topical skin restricted HDAC inhibitor, in a phase 1b study in cutaneous T cell lymphoma
Poster # 531
Location: Brazos, Albuquerque Convention Center
Suberohydroxamic acid phenyl ester, or SHAPE, is a histone deacetylase (HDAC) inhibitor being developed for topical use for the treatment of cutaneous T-cell lymphoma, or CTCL. SHAPE is a novel therapeutic intentionally designed to maximize HDAC inhibition locally in the skin with limited systemic exposure. As a result, SHAPE has characteristics that could allow it to be used topically over large body surface areas without systemic absorption. SHAPE demonstrated safety and clinical activity in a randomized, dose escalation placebo-controlled Phase 1 clinical trial in early CTCL subjects. A randomized Phase 2 clinical trial to evaluate SHAPE in early stage CTCL is expected to commence by the end of 2014. SHAPE's composition of matter patent in the U.S. extends until at least 2028; in addition, SHAPE has been granted U.S. orphan drug designation for CTCL. TetraLogic acquired worldwide development and commercialization rights to SHAPE for all indications.
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid phenyl ester (SHAPE). Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors. SHAPE is entering Phase 2 trials for early-stage CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic's pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19,2014. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT: Company Contact: Pete A. Meyers Chief Financial Officer and Treasurer TetraLogic Pharmaceuticals Corporation (610) 889-9900, x103 email@example.com Investor Relations Contact: Ami Bavishi Burns McClellan, Inc. (212) 213-0006 firstname.lastname@example.org